全文获取类型
收费全文 | 3101篇 |
免费 | 194篇 |
国内免费 | 31篇 |
专业分类
耳鼻咽喉 | 45篇 |
儿科学 | 53篇 |
妇产科学 | 50篇 |
基础医学 | 397篇 |
口腔科学 | 70篇 |
临床医学 | 233篇 |
内科学 | 858篇 |
皮肤病学 | 40篇 |
神经病学 | 241篇 |
特种医学 | 92篇 |
外科学 | 578篇 |
综合类 | 13篇 |
一般理论 | 2篇 |
预防医学 | 64篇 |
眼科学 | 23篇 |
药学 | 222篇 |
中国医学 | 13篇 |
肿瘤学 | 332篇 |
出版年
2023年 | 26篇 |
2022年 | 15篇 |
2021年 | 76篇 |
2020年 | 56篇 |
2019年 | 69篇 |
2018年 | 89篇 |
2017年 | 71篇 |
2016年 | 70篇 |
2015年 | 80篇 |
2014年 | 105篇 |
2013年 | 122篇 |
2012年 | 194篇 |
2011年 | 196篇 |
2010年 | 83篇 |
2009年 | 68篇 |
2008年 | 130篇 |
2007年 | 136篇 |
2006年 | 143篇 |
2005年 | 166篇 |
2004年 | 163篇 |
2003年 | 138篇 |
2002年 | 148篇 |
2001年 | 62篇 |
2000年 | 84篇 |
1999年 | 73篇 |
1998年 | 34篇 |
1997年 | 30篇 |
1996年 | 33篇 |
1995年 | 25篇 |
1994年 | 30篇 |
1993年 | 25篇 |
1992年 | 60篇 |
1991年 | 49篇 |
1990年 | 56篇 |
1989年 | 47篇 |
1988年 | 38篇 |
1987年 | 42篇 |
1986年 | 34篇 |
1985年 | 41篇 |
1984年 | 27篇 |
1983年 | 20篇 |
1982年 | 11篇 |
1981年 | 8篇 |
1979年 | 19篇 |
1978年 | 19篇 |
1977年 | 12篇 |
1974年 | 8篇 |
1973年 | 12篇 |
1971年 | 16篇 |
1970年 | 19篇 |
排序方式: 共有3326条查询结果,搜索用时 15 毫秒
1.
2.
Yosuke Homma Takashi Shiga Hiraku Funakoshi Dai Miyazaki Atsushi Sakurai Yoshio Tahara Ken Nagao Naohiro Yonemoto Arino Yaguchi Naoto Morimura 《The American journal of emergency medicine》2019,37(2):241-248
Objective
This study assessed the association between the timing of first epinephrine administration (EA) and the neurological outcomes following out-of-hospital cardiac arrests (OHCAs) with both initial shockable and non-shockable rhythms.Methods
This was a post-hoc analysis of a multicenter prospective cohort study (SOS-KANTO 2012), which registered OHCA patients in the Kanto region of Japan from January 2012 to March 2013. We included consecutive adult OHCA patients who received epinephrine. The primary result included 1-month favorable neurological outcomes defined as cerebral performance category (CPC) 1 or 2. Secondary results included 1-month survival and return of spontaneous circulation (ROSC) after arrival at the hospital. Multivariable logistic regression analysis determined the association between delay per minute of the time from call to first EA in both pre- or in-hospital settings and outcomes.Results
Of the 16,452 patients, 9344 were eligible for our analyses. In univariable analysis, the delay in EA was associated with decreased favorable neurological outcomes only when the initial rhythm was a non-shockable rhythm. In multivariable analyses, delay in EA was associated with decreased ROSC (adjusted odds ratio [OR] for one minute delay, 0.97; 95% confidence interval [CI], 0.96–0.98) and 1-month survival (adjusted OR, 0.95; 95% CI, 0.92–0.97) when the initial rhythm was a non-shockable rhythm, whereas during a shockable rhythm, delay in EA was not associated with decreased ROSC and 1-month survival.Conclusions
While assessing the effectiveness of epinephrine for OHCA, we should consider the time-limited effects of epinephrine. Additionally, consideration of early EA based on the pathophysiology is needed. 相似文献3.
High prevalence of toothache among Great East Japan Earthquake survivors living in temporary housing
4.
Yusuke Kagawa Hiromi Furuta Takehiro Uemura Naohiro Watanabe Junichi Shimizu Yoshitsugu Horio Hiroaki Kuroda Yoshitaka Inaba Takeshi Kodaira Katsuhiro Masago Shiro Fujita Akio Niimi Toyoaki Hida 《Cancer science》2020,111(12):4442
Immune checkpoint inhibitors (ICIs) have dramatically changed the strategy used to treat patients with non‐small‐cell lung cancer (NSCLC); however, the vast majority of patients eventually develop progressive disease (PD) and acquire resistance to ICIs. Some patients experience oligoprogressive disease. Few retrospective studies have evaluated clinical efficacy in patients with oligometastatic progression who received local therapy after ICI treatment. We conducted a retrospective analysis of advanced NSCLC patients who received PD‐1 inhibitor monotherapy with nivolumab or pembrolizumab to evaluate the effects of ICIs on the patterns of progression and the efficacy of local therapy for oligoprogressive disease. Of the 307 patients treated with ICIs, 148 were evaluated in our study; 42 were treated with pembrolizumab, and 106 were treated with nivolumab. Thirty‐eight patients showed oligoprogression. Male sex, a lack of driver mutations, and smoking history were significantly correlated with the risk of oligoprogression. Primary lesions were most frequently detected at oligoprogression sites (15 patients), and 6 patients experienced abdominal lymph node (LN) oligoprogression. Four patients showed evidence of new abdominal LN oligometastases. There was no significant difference in overall survival (OS) between the local therapy group and the switch therapy group (reached vs. not reached, P = .456). We summarized clinical data on the response of oligoprogressive NSCLC to ICI therapy. The results may help to elucidate the causes of ICI resistance and indicate that the use of local therapy as the initial treatment in this setting is feasible treatment option. 相似文献
5.
6.
Masahito Sawahata Daisuke Mori Yuko Arioka Hisako Kubo Itaru Kushima Kanako Kitagawa Akira Sobue Emiko Shishido Mariko Sekiguchi Akiko Kodama Ryosuke Ikeda Branko Aleksic Hiroki Kimura Kanako Ishizuka Taku Nagai Kozo Kaibuchi Toshitaka Nabeshima Kiyofumi Yamada Norio Ozaki 《Psychiatry and clinical neurosciences》2020,74(5):318-327
7.
8.
Kiyotaka Nemoto Tetsuya Shimokawa Masaki Fukunaga Fumio Yamashita Masashi Tamura Hidenaga Yamamori Yuka Yasuda Hirotsugu Azechi Noriko Kudo Yoshiyuki Watanabe Mikio Kido Tsutomu Takahashi Shinsuke Koike Naohiro Okada Yoji Hirano Toshiaki Onitsuka Hidenori Yamasue Michio Suzuki Kiyoto Kasai Ryota Hashimoto Tetsuaki Arai 《Psychiatry and clinical neurosciences》2020,74(1):56-63
9.
Naohiro Sekiguchi Shinya Rai Wataru Munakata Kenshi Suzuki Hiroshi Handa Hirohiko Shibayama Tomoyuki Endo Yasuhito Terui Noriko Iwaki Noriko Fukuhara Hiro Tatetsu Shinsuke Iida Takayuki Ishikawa Ryota Shiibashi Koji Izutsu 《Cancer science》2020,111(9):3327-3337
Tirabrutinib is a second‐generation Bruton’s tyrosine kinase inhibitor with greater selectivity than ibrutinib. Here, we conducted a multicenter, phase II study of tirabrutinib in patients with treatment‐naïve (Cohort A) or with relapsed/refractory (Cohort B) Waldenström’s macroglobulinemia (WM). Patients were treated with tirabrutinib 480 mg once daily. The primary endpoint was major response rate (MRR; ≥ partial response). Secondary endpoints included overall response rate (ORR; ≥ minor response), time to major response (TTMR), progression‐free survival (PFS), overall survival (OS), and safety. In total, 27 patients (18 in Cohort A; 9 in Cohort B) were enrolled. The median age was 71 y, and the median serum immunoglobulin M level was 3600 mg/dL. Among the patients, 96.2% had the MYD88L265P mutation. MRR and ORR were 88.9% and 96.3%, respectively (Cohort A: MRR, 88.9%; ORR, 94.4%; Cohort B: MRR, 88.9%; ORR, 100%). Median TTMR was 1.87 mo. PFS and OS were not reached with a median follow‐up of 6.5 and 8.3 mo for Cohorts A and B, respectively. The most common adverse events (AEs) were rash (44.4%), neutropenia (25.9%), and leukopenia (22.2%), with most AEs classified as grade 1 or 2. Grade ≥ 3 AEs included neutropenia (11.1%), lymphopenia (11.1%), and leukopenia (7.4%). No grade 5 AEs were noted. All bleeding events were grade 1; none were associated with drug‐related atrial fibrillation or hypertension. Although the follow‐up duration was relatively short, the study met the primary endpoint. Therefore, tirabrutinib monotherapy is considered to be highly effective for both untreated and relapsed/refractory WM with a manageable safety profile. (JapicCTI‐173646). 相似文献
10.
Naohiro Oda Takahiro Taki Reo Mitani Ichiro Takata 《Journal of infection and chemotherapy》2021,27(5):751-754
Herein, we report the case of a 74-year-old man diagnosed with Legionella pneumonia detected by Loop-Mediated Isothermal Amplification (LAMP) method, which was suspected to have been transmitted from the potting soil. Legionella longbeachae was identified in the sputum culture. The patient was intubated and maintained on mechanical ventilation. Antimicrobial therapy with azithromycin was also administered. His symptoms were resolved and he was discharged after 26 days of hospitalization. Legionella longbeachae pneumonia rarely occurs in Japan, and published literature of Legionella longbeachae pneumonia cases in Japan was reviewed. Patients with severe pneumonia exposed to potting soils, but with negative urinary antigen test results, should be examined by LAMP method. 相似文献